Silence Therapeutics GmbH

Forschungsschwerpunkte: Successful completion of clinical phase I study in oncology (Atu027) and phase 2 study (Atu027) in process. Issued patents in US, EU and other jurisdiction for its core technologies (AtuRNAi, Delivery Systems).

  • Mitarbeiterzahl

    44
  • Ausrichtungen
    • Therapie-Entwickler
  • Gegründet

    1998
  • Aktualisiert am

    30.05.2018